The p53 tumor suppressor is a transcription factor that activates the expression of many target genes. We have previously reported the identi®cation of a p53-regulated mouse gene DDA3. The 5' upstream genomic region of the mouse DDA3 was cloned, and sequence analysis revealed the presence of a potential p53 response element (RE2) residing at nucleotides +390*+409 relative to the ®rst translation start site. When fused upstream to a luciferase reporter gene, 5' genomic regions of the DDA3 gene containing RE2 were shown to be responsive to the wild-type, but not mutant p53, in a transient transfection assay. RE2 was sucient to confer the transactivation responsiveness to p53. Furthermore, gel mobility shift analysis showed that RE2 formed speci®c complexes with wild-type p53. Induction of DDA3 was found in adriamycin treated normal mouse embryonic ®broblast cells (MEF), but not in p53 knockout (p53
Introduction
The tumor suppressor p53 is a guardian of the genome that plays an important role in suppressing cancer development (Lane, 1992; Ryan et al., 2001) , and mutation on the p53 gene ranks as the most common genetic events in human cancers (Hollstein et al., 1991; Levine et al., 1991) . A large body of evidence indicates that p53 is required for maintaining the integrity of the genome under environmental stresses. For example, when cells are exposed to DNA damaging agents such as UV radiation or chemotherapeutic drugs, the amount and/or activity of p53 is increased, which leads to cell cycle arrest and apoptosis (Oren, 1994; Levine, 1997; Vogelstein et al., 2000) . In addition to DNA damage, p53 also serves as a sensor for microtubule integrity (Cross et al., 1995) , nucleotide levels (Linke et al., 1996) and cellular oxygen supply (Graeber et al., 1994) . In the presence of inhibitors for microtubule assembly and nucleotide synthesis, or when cells are under hypoxia, p53 is activated and renders the cells unable to progress through the cell cycle.
p53 is a transcription factor capable of activating the transcription of genes carrying distinct p53 binding motif of the consensus sequence 5'-PuPuPuC(A/T)(T/ A)GPyPyPy-3' (Farmer et al., 1992; El-Deiry et al., 1992) . The majority of p53 mutations found in cancers are point mutations clustered within its DNA binding domain; these mutations disrupt its interaction with DNA and render the p53 protein transcriptionally inactive (Harris, 1993) . It is therefore conceivable that many of the downstream transcriptional targets of p53 act as important mediators for the tumor suppressor function of p53.
An increasing number of p53 target genes have been identi®ed; they account in part for p53-mediated checkpoint control, apoptosis and DNA repair. Among these is the p21 Waf1/Cip1 cyclin-dependent kinase inhibitor (El-Deiry et al., 1993; Harper et al., 1993) , which can block DNA replication by inhibiting the proliferating cell nuclear antigen-dependent DNA polymerase (Li et al., 1994) . Substantial evidence suggests that p53-mediated G 1 growth arrest proceeds primarily through the induction of p21 Waf1/Cip1 (Deng et al., 1995) . p53 is also involved in controlling G 2 /M progression (Agarwal et al., 1995; Stewart et al., 1995; Aloni-Grinstein et al., 1995) , yet the contribution made by p53 to the regulation of G 2 checkpoint is less clear. There are indeed p53 targets, e.g. B99 (Utrera et al., 1998) , BTG2 (Rouault et al., 1996 ), 14-3-3-s (Hermeking et al., 1997 , Reprimo (Ohki et al., 2000) , and MCG10 (Zhu and Chen, 2000) , implicated in regulating the progression of cell cycle through G 2 /M; and overexpression of these genes in cells impedes G2/M progression. The link between p53 and apoptosis is provided by a number of apoptosis-related genes that have been shown to be direct p53 targets. The products of these genes, including BAX (Miyashita and Reed, 1995) , NOXA (Oda et al., 2000a) , p53AIP1 (Oda et al., 2000b) , and PUMA (Yu et al., 2001) , interact with BCL-2 family members, and contribute to the apoptosis promoting activity of p53.
Recently, homologues of p53, such as p63 and p73, have been identi®ed (Kaghad et al., 1997; Schmale and Bamberger, 1997; Trink et al., 1998; Yang et al., 1998) . The p73a protein and its alternatively spliced variants b, g and d share extensive sequence homology to p53 in the conserved regions, including transactivation, DNA binding, and oligomerization domains (Kaghad et al., 1997; De Laurenzi et al., 1998; Marin and Kaelin, 2000) . It is therefore not surprising that p73 transactivates many of the p53 cellular target genes. Although induction of p73 is not detectable under UV radiation, elevated levels of p73 expression are evident in cells undergoing cisplatin-induced DNA damages (Kaghad et al., 1997; Gong et al., 1999) . Similar to p53, expression of p73 induces cell cycle arrest and apoptosis (Irwin and Kaelin, 2001; Yuan et al., 1999; Lohrum and Vousden, 2000; Zhu et al., 1998) . It thus appears that isoforms of p73 share functional similarity with p53.
Through mRNA dierential display on IW32 murine erythroleukemia cells transfected with a temperaturesensitive p53 mutant gene tsp53
Val135 , we have previously identi®ed a p53-regulated gene designated DDA3 (Lo et al., 1999) . The induction of DDA3 mRNA is dependent on RNA but not new protein synthesis, suggesting that DDA3 is a direct transcriptional target of p53. When overexpressed in mammalian cells, DDA3 inhibits cell growth as shown by colony formation assay. DDA3 encodes a serine-and proline-rich protein containing a coiled-coil region plus six putative SH3-domain binding motifs PXXP (P for proline and X, any amino acid); it therefore may provide a point of interaction for p53 with other signaling pathways and contribute to the complexity and speci®city of p53 signaling networks. In this study, we report the cloning of the 5' genomic region of the mouse DDA3 gene and identi®cation of an intronic p53 response element that confers the p53-responsiveness of DDA3. In addition, we show that isoforms of p73 are able to induce DDA3 expression; the same intronic p53 response element within the DDA3 gene is responsive to the p73-mediated transactivation. These ®ndings list DDA3 as a direct transcriptional target gene of p53 and p73.
Results

Cloning of the 5' genomic region of mouse DDA3 gene
We have previously identi®ed the mouse DDA3 as a DNA damage-inducible and p53-regulated gene. To determine whether DDA3 is indeed a bona ®de transcriptional target gene of p53, we cloned the 5' upstream region of the mouse DDA3 gene through PCR-based genome walking (See Materials and methods). From sequences of the PCR products, a nucleotide sequence of 3056 bp in length was compiled (DDBJ/EMBL/GenBank accession No. AF284692). By comparing the genomic sequence with the mouse DDA3 cDNA for exon-intron boundaries, the genomic fragment we've cloned is deduced to contain the gene from 72287 to +769 of the DDA3 gene (+1 is de®ned as the A of the ®rst translation initiation codon); this region includes the 5'-upstream sequence and the coding region from exon 1 to part of exon 4 (Figure 1a ). An examination of the sequence revealed the presence of two putative p53 binding sites, one located at 71189/71216 (RE1), and the second resides within the third intron (RE2, +390/+409). A schematic diagram of the partial DDA3 locus with relative locations of RE1 and RE2 is shown in Figure  1a . The nucleotide sequence of RE1 contains two Figure 1 (a) The structure of the 5' genomic region of the DDA3 gene containing the putative p53-binding sites. Boxes represent exons. The positions of the p53 response element consensus sequences RE1 and RE2 are marked relative to the ATG translation initiation site (+1). Alignment of the consensus (CON) p53-binding site sequence with that of RE1 and RE2 is shown, the consensus half sites are underlined and mismatches are indicated by lower case letters. RE1 contains two half-sites separated by eight nucleotides (N8), and with a cytosine replacing the conserved guanine in the ®rst half site. Mutations are introduced into mRE2 at the residues denoted by arrowheads. (b) A schematic diagram of the DDA3 5' genomic fragmentluciferase fusion constructs used in this study. Numbers refer to nucleotides relative to the ®rst translation initiation site, positions of RE1 and RE2 are indicated decamers separated by 8 bp; the decamers match the previously de®ned p53 binding site consensus, except at position 7 of the ®rst decamer where cytosine replaces the conserved guanine. On the other hand, RE2 contains two contiguous decamers matching the consensus p53-binding motif in 19 out of 20 positions; a mismatch is located at position 10 of the ®rst decamer.
5' genomic regions of DDA3 containing RE2 confer responsiveness to p53 activation
To explore the functional signi®cance of these potential p53-binding sites, genomic fragments of the mouse DDA3 gene harboring RE1 and/or RE2 were placed upstream to the luciferase gene in the promoterless pGL2-Basic plasmid. A schematic map of genomic fragments constructed for the transient reporter assay is shown in Figure 1b . pGL2-B1, which contains DDA3 fragment 72228 to +412, includes both RE1 and RE2; pGL2-B2 (72228 to +170) and pGL2-B3 (71055 to +412) contain RE1 and RE2, respectively; and pGL2-B4 (71055 to +170) retains neither RE1 or RE2. These plasmids were separately transfected with vectors expressing either wild-type, or the transactivation-defective mutant p53 (p53 R175H ), into the p53-de®cient-H1299 non-small cell lung carcinoma cells. As shown in Figure 2 , wild-type p53 signi®cantly increased luciferase activity (28-fold) when transfected with pGL2-B1 that contains both RE1 and RE2, indicating that this region of the DDA3 gene conferred the p53 responsiveness. On the other hand, pGL2-B2, which has the RE2 region deleted, was no longer responsive to wild-type p53 activation. pGL2-B3, which retains only RE2, was activated to a comparable level (23-fold) as pGL2-B1 by wild-type p53, and pGL2-B4, containing neither RE1 or RE2, was not activated by p53. The activation was dependent on functional p53 since the transactivation-defective mutant p53 R175H was incapable of activating the reporter constructs. These results demonstrate that the 5-genomic regions of the DDA3 gene containing RE2 conferred responsiveness to p53 activation.
RE2 binds p53 and is sufficient for p53-mediated activation
The above results in conjunction with the sequence homology between RE2 and p53 binding motif suggest that the intronic RE2 may be responsible for p53-mediated transactivation. If RE2 is truly a p53 responsive element, it should be able to respond to p53 when fused to a heterologous promoter. To test this hypothesis, the oligonucleotides corresponding to the RE2 sequence were synthesized and placed upstream to the luciferase gene driven by a minimum TATA promoter (pGL2-TATA). Cotransfection of pGL2-RE2 with wild-type p53 into H1299 cells resulted in more than 30-fold stimulation of the luciferase activity ( Figure 3 ). The activation was dependent on functional p53 since p53 R175H was unable to induce the luciferase activity. Moreover, mRE2, which carries mutations at the fourth and seventh positions in both decamers of RE2 (Figure 1a ), was not responsive to wild-type p53 activation, nor was RE1 or the vector alone control (TATA). These results indicate that RE2 alone can support the p53-mediated transcriptional activation.
To examine whether p53 binds directly to oligonucleotides corresponding to the RE2 sequence, we performed the electrophoretic-mobility shift assay. The RE2 was synthesized and radiolabeled, the probe was incubated with nuclear extracts prepared from H1299 cells transfected with plasmids expressing either Figure 2 Segments of DDA3 5' genomic region containing RE2 are responsive to p53 activation. H1299 cells were cotransfected with the indicated luciferase reporter constructs and plasmids expressing wild-type p53 (wtp53), the transactivation defective p53 R175H (mtp53), or the vector control pRcCMV. Cells were harvested 24 h after transfection and total cell lysates prepared for measurement of luciferase activity. The luciferase activity was normalized with the activity of b-galactosidase whose expression was supported by the plasmid introduced as a transfection eciency control. Fold of activation was calculated by arbitrarily setting the activity obtained from vector-transfected cells as 1 Figure 3 RE2 is sucient in mediating p53 transactivation in a heterologous promoter. The putative p53 response elements RE1 and RE2 were cloned upstream to a luciferase reporter plasmid pGL2-TATA. The reporter constructs (0.5 mg) were cotransfected with the same amount of vectors expressing either wild-type (wtp53), transactivation defective mutant p53 R175H (mtp53), or the vector control pRcCMV. Luciferase activity was measured 24 h after transfection, and was normalized with the activity of bgalactosidase expressed from a transfection eciency control vector. The relative luciferase activity from the cells cotransfected with pRcCMV was arbitrarily set as one for calculation of fold induction. Results are means+standard deviations from three independent experiments wild-type p53 or p53 R175H . As shown in Figure 4a , a complex with shifted gel mobility (arrowhead) was detected when the wild-type p53-containing extract (wt) was incubated with RE2 probe. Moreover, this slow migrating band could be supershifted by the anti-p53 antibody pAb421, as demonstrated by the presence of two new bands with lower gel mobility (asterisk). In contrast, nuclear extracts from mutant p53-transfected H1299 cells (mt) or from nontransfected-control cells failed to form any speci®c ternary complex with RE2 DNA and pAb421 antibody. The speci®city of RE2-p53 binding was also demonstrated by a competition experiment. In the presence of excess unlabeled RE2 oligonucleotides, ternary complex formation was inhibited signi®cantly, whereas mRE2 had no appreciable eect on RE2-p53 binding, nor did synthetic oligonucleotides containing RE1 (Figure 4b) . The above observations were essentially reproducible using p53 containing-extracts prepared from dierent sources. As indicated in Figure 4c , in the presence of pAb421, a temperature-sensitive tsp53
Val135 allele expressing extracts from IW32-derived cell line (clone 1 ± 5) cultured at 328C (permissive temperature) formed a speci®c complex with RE2 (asterisk). Furthermore, this complex could be displaced by the presence of excess unlabeled RE2, but not by RE1 or mRE2, whereas extracts from parental IW32 cells that did not produce functional p53 were unable to bind RE2. We next examined if extracts prepared from DNA damageinduced cells that expressed elevated levels of endogenous wild-type p53 also contained RE2 binding activity. NIH3T3 cells were treated with adriamycin (ADR) under condition that enhances wild-type p53 expression (Lo et al., 1999) , and the nuclear extracts were prepared and incubated with RE2 DNA in the presence or absence of pAb421. As indicated in Figure  4d , incubation with anti-p53 antibody resulted in two slow migrating bands (asterisk) that could be inhibited by the presence of excess unlabeled RE2, but not by RE1 or mRE2. Control cells not treated with adriamycin displayed very low amount of RE2 binding activities due to basal levels of wild-type p53 expression in these cells. These results clearly showed that RE2 within the mouse DDA3 gene binds speci®cally to wild-type p53 in extracts prepared from p53 overexpressing or DNA damage-induced cells.
Induction of DDA3 by DNA damage is p53 dependent
The p53 dependent activation of DDA3 was further examined using MEF cells from normal (p53 +/+ ) and p53 knockout (p53 7/7 ) mice. These cells were treated with DNA damaging drug adriamycin for up to 16 h, and Northern blotting was performed to monitor the mRNA expression of DDA3. As shown in Figure 5a , elevated expression of DDA3 and p21
Waf1/Cip1 transcripts was found in adriamycin treated p53 +/+ MEF cells; in contrast, no induction of these genes could be observed in p53 7/7 MEF cells under the same treatment. In line with increased DDA3 mRNA expression, Western blot analysis using DDA3 speci®c antibodies showed a prominent increase of DDA3 protein in p53 +/+ MEF after adriamycin treatment, but not in p53 7/7 MEF cells ( Figure 5b) ; increased p53 protein expression in p53 +/+ MEF cells treated with adriamycin was also con®rmed using speci®c p53 antibody (Figure 5b ). These results clearly show that DDA3 is induced by the adriamycin-mediated DNA damage in a p53-dependent manner. R175H (mt) or vector alone (7) for 24 h. 10 mg of each nuclear extract was incubated with 32 P-labeled RE2 for 30 min in the presence (+) or absence (7) of p53 speci®c antibody pAb421. The mixtures were separated by electrophoresis on non-denaturing polyacryamide gel as described in the Materials and methods and the autoradiograph of the gel is shown. (b) Nuclear extracts were prepared from H1299 cells and binding was performed in the presence of pAb421 as stated above, except that 30-fold molar excess of unlabeled RE1, RE2 or mutated RE2 (mRE2) was added as indicated. (c) Nuclear extracts were prepared from parental IW32 cells and its tsp53
Vall35 transfectant (clone 1 ± 5) cells cultured at 328C. The extracts were incubated with 32 Plabeled RE2 in the presence (+) or absence (7) of pAb421 or unlabeled nucleotides of RE2, mRE2, and RE1 as indicated. The reaction mixtures were analysed by gel mobility shift analysis as described in the Materials and methods. (d) Nuclear extract were prepared from NIH3T3 cells treated with (ADR) or without (C) adriamycin. The extracts were incubated with 32 P-labeled RE2 in the presence (+) or absence (7) of pAb421 and unlabeled competitor nucleotides as indicated. The reaction mixture was analysed by gel mobility shift analysis as described in the Materials and methods. Arrows in these ®gures indicate p53-DNA complex and asterisks represent ternary complex between p53, DNA and pAb421
DDA3 is a transcriptional target gene of p73
As there is extensive sequence homology in DNA binding domains of p53 and p73, and therefore the two proteins likely have common transcriptional target genes, we examined the transactivation potential of p73 for DDA3. H1299 cells were transiently cotransfected with vectors expressing p73 isoforms a, b, g and d, together with the reporter constructs containing RE1, RE2, and mRE2 placed upstream to the luciferase gene in pGL2-TATA. Analysis of the luciferase activity in the transfected cells indicated that, similar to p53, all four isoforms of p73 were able to transactivate reporter constructs that contained RE2 (Figure 6 ), whereas RE1 and mRE2 were not responsive to p73-mediated transactivation. We also observed signi®cant dierences in the transactivating activity among the p73 isoforms as reported by others (Zhu et al., 1998; Di Como et al., 1999; Lee and Thangue, 1999) . p73b and d activated the RE2-mediated luciferase activity to greater than 80-fold, which was higher than that attained by p53 (40-fold); the least extent of luciferase stimulation was obtained with p73g (10-fold).
We next examined if expression of p73 leads to DDA3 induction. The p53
MEF cells were transiently transfected with vectors expressing p73 a or b, and DDA3 expression was analysed by Northern blotting. As shown in Figure 7a , levels of DDA3 mRNA increased signi®cantly in cells transiently ) MEF. Total RNA was extracted at the indicated time points after treatment and subjected to Northern blot analysis for the expression of mouse DDA3 and p21 Waf1/Cip1 as described in the Materials and methods. The expression of GAPDH was included as a RNA loading control. (b) Induction of DDA3 protein by DNA damage. Cells were treated as in (a) nuclear extracts were prepared and 25 mg per lane were separated by electrophoresis on a 10% SDSpolyacrylamide gel. The protein was blotted to a nitrocellulose membrane and reacted with a polyclonal anti-DDA3 antibody. The same blot was reprobed by p53 speci®c antibody Figure 6 RE2 is sucient in mediating p73 transactivation in a heterologous promoter. H1299 cells were cotransfected with reporter constructs (Figure 3 ) and vectors expressing p53 or isoforms of p73. After 24 h, cell lysates were prepared and measured for luciferase activity. Luciferase activity was normalized with the activity of b-galactosidase from the vector introduced as a transfection eciency control. The relative luciferase activities from cells cotransfected with pGL2-TATA were arbitrarily set as one for calculation of fold induction.
Results are means+standard deviations from three independent experiments
Figure 7 p73 overexpression activates DDA3. (a) The expression of mouse DDA3 mRNA. Total RNA from p53 7/7 MEF cells transfected with either empty vector pcDNA3 (vector), or vectors expressing p73a and p73b as indicated was analysed by Northern blotting using 32 P-labeled DDA3 as probe. GAPDH was included as a RNA loading control. (b) Western blot analysis of cells treated as in (a). Total cell extracts were prepared and 30 mg of proteins were separated by electrophoresis on a SDS-polyacrylamide gel. The proteins were blotted to a nitrocellulose membrane and reacted with a p73 speci®c antibody (SantaCruz) transfected with p73 a and b, but not in control vector transfected cells. As demonstrated in Figure 7b , Western blot analysis using speci®c antibodies for p73 a and b con®rmed that these two proteins were indeed expressed in the transfected cells, indicating that the increase of DDA3 levels was p73-dependent.
It has been shown that DNA damage induced by UV radiation or actinomycin D was unable to activate p73 (Kaghad et al., 1997) , however, elevated expression of p73 was observed in cells treated with DNA damaging drug cisplatin (Gong et al., 1999) . If DDA3 is a transcriptional target of p73, it should be possible to detect its induction in p53 7/7 MEF cells treated with cisplatin. To test this possibility, MEF cells from p53 7/7 mice were exposed to cisplatin, and RNA was examined by Northern blotting for DDA3 expression. As seen in Figure 8a , basal mDDA3 levels was much lower in the p53 7/7 MEF cells as compared to that in the wild-type MEF cells, however, a modest but signi®cant induction of DDA3 mRNA expression was consistently observed in these cells treated with cisplatin; indicating that there is a p53-independent activation pathway for DDA3. Western blot analysis showed a paralleled elevation of p73 levels in cells exposed to cisplatin (Figure 8b ). Under the same circumstances, the p21 Waf1/Cip1 mRNA expression was undetectable in the p53 7/7 cells treated with or without cisplatin. These results demonstrated that DDA3 is a transcriptional target gene of p73.
Discussion
The ability of p53 to transactivate genes containing speci®c binding motifs is central to its role as a tumor suppressor. We report here the identi®cation of an intronic p53-response element in a previously characterized p53-regulated mouse gene, DDA3. The conclusion that DDA3 is a direct p53 downstream target gene is drawn from several lines of evidence. First, segments of the DDA3 gene containing the putative p53-binding motif RE2 conferred the p53-mediated transactivation in the transient transfection assay. In conjunction with a heterologous promoter, RE2 also supported transcriptional induction by p53, suggesting that RE2 is sucient in mediating p53 transactivation. Moreover, RE2 formed complexes with wild-type p53 but not with the transactivation defective mutant p53. The speci®c binding between p53 and RE2 was observed with cell lysates prepared from p53 overexpressing cells as well as from DNA damageinduced cells expressing endogenous p53. Finally, DDA3 induction was observed in DNA damageinduced normal MEF cells, but not in p53 knockout MEF cells.
We have previously shown that overexpression of DDA3 inhibits colony formation (Lo et al., 1999) , suggesting that it mediates, at least in part, the p53-induced growth suppression. The present ®nding that DDA3 mRNA increases in a p53-dependent manner in MEF cells undergoing drug induced DNA damage indicates that DDA3 is a physiological target of p53. Examination of the deduced amino acid sequence of DDA3 reveals the presence of multiple potential phosphorylation sites for protein kinase A and C, casein kinase II, and cyclic GMP dependent protein kinase; it is conceivable that the activity of DDA3 could be modulated through phosphorylation by cellular signaling components. In addition, DDA3 contains six PXXP motifs, which are potential interaction sites for the SH3 domain, which is employed extensively as a binding motif for downstream components of growth factor-and cytokinemediated signaling. Although the biological signi®-cance of DDA3 induction with respect to p53 function remains to be elucidated, the identi®cation of DDA3 as an additional p53 target strengthens the link between p53 and the components of the cellular signaling pathways. It is tempting to speculate that by incorporating DDA3 as its direct target, p53 may exert its eect through cross interaction with cellular growth regulatory signaling pathways.
Aside from p53, we have shown that isoforms of p73 are capable of transactivating DDA3 when overexpressed in cells. p73 is a key downstream component of c-ABL-mediated DNA damage response. Similar to p53, expression of p73 induces growth arrest and apoptosis. Unlike p53, level of p73 protein is not responsive to UV irradiation or actinomycin D treatment. It is, however, stabilized during DNAdamage induced by cisplatin or g-irradiation in a c-ABL dependent pathway (Gong et al., 1999; Agami et al., 1999) . The existence of p53-independent p73-mediated activation of DDA3 is revealed by the observation that enhanced DDA3 mRNA was detected in the p53 7/7 MEF cells undergoing DNA damage induced by cisplatin. As shown by the transient MEF cells were treated with (+) or without (7) cisplatin as in (a) and total cell extract was prepared, 200 mg of lysate was separated by 10% SDS ± PAGE, blotted to a nitrocellulose paper and reacted with polyclonal antibody against p73 (SantaCruz). As a positive control for p73a expression, cells were transfected with p73a expression plasmid, and 30 mg of the cell extracts were analysed by SDS-polyacrylamide gel electrophoresis. The immunoreactive bands were detected by chemiluminescence (NEN Life Science) transfection analysis, RE2 alone is sucient to confer the p73-mediated transactivation. The extent of RE2-mediated activation of DDA3 by dierent isoforms of p73 varied signi®cantly, and the activation by p73b is consistently higher than that by p53 or other p73 isoforms, suggesting that DDA3 may be a bona ®de cellular target of p73. Many of the p53 cellular target genes are also activated by p73. Interestingly, despite extensive homology between these two proteins in their DNA binding and transactivation domains, p73 dierentially activates some but not all p53 target genes. Zhu et al. (1998) have shown that upregulation of 14-3-3s by p73 is signi®cantly higher than that by p53; on the other hand, p21
Waf1/Cip1 or GADD45 is activated by p73 to a lower extent, while BAX and some redox-related genes are not signi®cantly induced by p73 at all. We have also shown that in clear contrast to DDA3, p21 Waf1/Cip1 is not expressed in p53 7/7 MEF cells, nor is it activated by exposing the cells to cisplatin. These results are consistent with the previous ®ndings that p73 dierentially regulates p53 downstream target genes. Evidence that p73 is similar to and dierent from p53 in activating their target genes strengthens the notion that these two proteins may cooperate in overlapping but distinct growth/apoptosis signaling pathway in response to stress invoked by dierent forms of DNA damages.
Materials and methods
Cell culture
H1299 non-small cell lung carcinoma cells and a subclone (clone 1 ± 5) of IW32 erythroleukemia cells stably expressing the temperature-sensitive tsp53
Val135 allele (Tang and Wang, 2000) were maintained in HEPES-buered RPMI with 10% fetal bovine serum and 50 mg/ml of gentamicin in 5% CO 2 at 378C. Temperature shifting was performed by transferring the subcon¯uent cells to the pre-equilibrated incubator at 328C. Mouse NIH3T3 ®broblast cells were grown in DMEM containing 10% calf serum, 100 U/ml of penicillin and 100 mg/ml of streptomycin in 5% CO 2 at 378C; cells were subcultured every 3 days. Mouse embryonic ®broblast (MEF) cells were prepared by sacri®cing mice between day 13 ± 14 of pregnancy as described (Tanaka et al., 1994) . The cells were kept in DMEM with 10% fetal bovine serum, 1 mM each of non-essential amino acids, 20 mM L-glutamine, 100 U/ml of penicillin and 100 mg/ml of streptomycin in 5% CO 2 at 378C. To activate endogenous p53, cells were grown to 80% con¯uence and then treated with adriamycin (400 ng/ml) for up to 16 h.
Plasmids
Vectors expressing wild-type p53 and the transactivation defective p53
R175H under the control of cytomegalovirus (CMV) early promoter were obtained from Dr J Lin, University of Michigan, USA. The pcDNA constructs expressing the full-length human cDNAs of p73a, b, g, and d were kindly provided by Dr G Melino, University of Rome, Italy. Reporter plasmids containing the luciferase reporter gene fused to DDA3 promoter of various lengths (Figure 1b) were constructed by ligating the PCR ampli®ed DDA3 fragments to pGL2-Basic (Promega).
Cloning of 5' genomic region of mouse DDA3 gene
To clone the upstream and exon 1 to 4 region of the mouse DDA3 gene, mouse genomic DNAs included in the Genome Walker Kit from Clontech were used as templates in a polymerase chain reaction (PCR) with two primers, primary (GSP1: 5'-TGGGCGAGGCCCCGTCGAAGTGGTTTCTC-3') and nested primers (GSP2: 5'-TGGACTCACTAATAC-TGTTATGTCTTCTTCCTC-3'), that anneal to the exon 4 region of the DDA3 gene. The PCR was carried out in a reaction mixture of 50 ml containing the following components: 5 ml of 106Tth PCR reaction buer (400 mM TrisHCl, pH 9.3, 150 mM KOAc), 1 ml each of 10 mM dNTPs, 2.2 ml of 25 mM Mg(OAc) 2 , 1 ml of 10 mM AP1 (adaptor primer 1, 5'-GTAATACGACTCACTATAGGGC-3'), 1 ml of 10 mM GSP1, and 1 ml of 506 Advantage genomic polymerase mix (5 ± 6 U/ml Tth DNA polymerase, 0.5 mg/ml Tth start antibody, 50% glycerol, 10 mM Tris-HCl (pH 7.5), 230 mM KCl, 0.075 mM EDTA, 0.75 mM dithiothreitol and 365 mg/ml bovine serum albumin). The reaction was started by adding 1 ml (5 ng) each of the Genome Walker DNA Library to the PCR mix. The cycling reactions were performed as follows: seven cycles of 948C for 2 s and 728C for 3 min, followed by 32 cycles of cycling step (948C for 2 s and 678C for 3 min), and a ®nal 4 min at 678C for elongation. One ml of the primary PCR products was diluted to 50 ml to be used as templates for nested PCR reactions using the same temperature cycle except that adaptor primer AP1 and GSP1 were replaced by AP2 (5'-ACTATAGGG-CACGCGTGGT-3') and GSP2. The nested PCR products were puri®ed by QIAEX II kit (QIAGEN) and directly cloned into the pGEM-T vector (Promega) for sequencing and further analysis.
Transfection and luciferase assay
For transfection, cells were seeded at 1610 5 cells per well in 12-well-plates and transfected with 0.5 mg each of the plasmid DNA by lipofectamine Plus TM reagents (GIBCO ± BRL). Cells were harvested at 24 h after transfection. Total cell lysates were prepared and luciferase activities were determined. The activity of luciferase was normalized to that of the b-galactosidase, since a plasmid carrying the LacZ gene under CMV promoter control was cotransfected as a transfection eciency control. All experiments were performed in triplicates, with transfection repeated for at least three times.
Gel mobility shift assay
Nuclear extracts were prepared according to McLure and Lee, 1998 with some modi®cations. RE2 was prepared by annealing two synthetic oligonucleotides with the sequences 5'-CCTGGGCATGTTGAGGCATGCCCTG-3' and 5'-ACGCGCAGGGCATGCCTCAACATGCCCAGG-3'. The probe was radiolabeled with Klenow enzyme in the presence of [a- 32 P]dCTP. Binding was performed by incubating nuclear extract with radiolabeled probe (2610 5 c.p.m.) in a buer containing 10 mM HEPES, pH 7.6, 1 mg poly dI-dC, 0.1% NP-40, 10% glycerol, 1 mM DTT, 5 mM MgCl 2 , pH 7.5, and 50 mM NaCl, in the presence or absence of anti-p53 antibody pAb421(0.2 mg). The reaction was allowed to proceed for 30 min, the protein-DNA interaction was analysed by electrophoresis on a non-denaturing 4% polyacrylamide gel.
